What is the role of vasoreactivity testing in the workup of pulmonary arterial hypertension (PAH)?

Updated: Apr 25, 2018
  • Author: Kristin E Schwab, MD; Chief Editor: Zab Mosenifar, MD, FACP, FCCP  more...
  • Print

Vasoreactivity testing is indicated in patients with hereditary, idiopathic, and anorexigen-induced PAH. [22] Acute vasoreactivity is determined by administering a short-acting vasodilator such as prostacyclin, inhaled nitric oxide, or adenosine. A positive vasoreactivity test requires that multiple conditions are met, such that (1) a decrease in mean pulmonary artery pressure of at least 10 mm Hg, (2) to a value less than 40 mm Hg, and (3) without a concurrent decrease in carbon monoxide or blood pressure

An acute response often predicts a beneficial effect from oral agents, such as calcium channel blockers. [23]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!